| Literature DB >> 26509228 |
Lisa Salvatore1,2, Daniele Rossini1,2, Roberto Moretto1,2, Chiara Cremolini1,2, Marta Schirripa1,2, Carlotta Antoniotti1,2, Federica Marmorino1,2, Fotios Loupakis1,2, Alfredo Falcone1,2, Gianluca Masi1,2.
Abstract
The survival of patients with metastatic colorectal cancer has notably increased in the past 20 years, from 12 months to around 30 months. Nevertheless, the prognosis of patients pretreated with all available agents is poor and there is high unmet need for newer treatments. TAS-102 is an orally administered combination of the nucleoside analogue trifluridine and tipiracil hydrochloride, a thymidine phosphorylase inhibitor. In a randomized trial of 800 patients who had received at least two other treatments previously (most patients had received more than four treatments). TAS-102 demonstrated a significant prolongation of overall survival compared with placebo (median survival 7.1 vs. 5.3 months; hazard ratio 0 · 68, 95%CI: 0 · 58-0 · 81; p < 0 · 001). The toxicity was manageable, grade 3 or higher events occurred in 69% of patients in the TAS-102 group versus 52% in the placebo group, with neutropenia the most common event.Entities:
Keywords: TAS-102; fluoropyrimidines; metastatic colorectal cancer; refractory; regorafenib
Mesh：
Substances：
Year: 2015 PMID： 26509228 DOI： 10.1586/14737140.2015.1105746
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN： 1473-7140 Impact factor: 4.512